The Cancer Drug Development Forum – CDDF is the platform for all stakeholders involved in the development of cancer drugs.

Cancer Drug Development Forum (CDDF) opened the Annual Conference 2023 yesterday with more than 150 people joining onsite and online.

Here are the Take-Home Messages from the first day of the Annual Conference:
• Diversity can be understood as the combination of generalisability and representativeness of the clinical trials results. (Carole Longson)
• There is a definite need for well defined variables to capture diversity in clinical trials with the aim to ensure best possible care for everyone. Many barriers still need to be overcome to achieve the diversity goals not the least some adverse cultural barriers. (Marie von Lilienfeld-Toal)
• Absence of evidence for efficacy is not the same as evidence for absence of efficacy. (Gilliosa Spurrier-Bernard)
• Improving data diversity improves AI utility and requires a strategy for (mindful) data collection, data preprocessing, multimodality, model training and evaluation to avoid bias. (David Cahané)

Cancer Drug Development Forum asbl
Registered office: c/o BLSI, Clos Chapelle-aux-Champs 30, 1200 Woluwe Saint Lambert, Belgium
Register of legal entities: the French Speaking Enterprise Court in Brussels
Enterprise number: 738.523.752
Tel: +32 2 880 62 70